** Shares of WuXi XDC Cayman Inc 2268.HK, a Chinese antibody drug conjugates research, development and manufacturing services provider, jump 14.5% to HK$56.55, their highest level since debut in November 2023
** Stock marks its biggest intraday pct gain since July 31, 2024 and on track to snap three straight sessions of losses, if current trend continues
** Top pct gainer in healthcare index .HSCIH, which is up 1.2%
** Co expects H1 net profit to increase more than 50% y/y, with revenue up over 60% y/y, due to growth of downstream demand in antibody drug conjugate and broader bioconjugate industry, among others
** Hang Seng Biotech Index .HSHKBIO rises 1.1%, benchmark Hang Seng Index .HSI climbs 0.6%
** YTD, stock up 81.4%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.